USANew treatments and approvals
Oral mitapivat approved in the USA for anemia in thalassemia
A decision by a medicines regulator (FDA, European Commission, etc.). The regulator has reviewed the clinical studies behind the drug. For accelerated or conditional approvals, the lasting benefit is still being confirmed.
The FDA has approved mitapivat for the treatment of anemia in adults with alpha- or beta-thalassemia. The approval covers both transfusion-dependent and non-transfusion-dependent patients. The drug carries a boxed warning because of the risk of liver damage. It is given under a special risk management program. Under this program, a liver test is needed every 4 weeks for the first 6 months.
What does it mean for patients and families?
A new oral option for adults with thalassemia. But regular liver monitoring is essential. Availability in Türkiye depends on TİTCK (Turkish Medicines and Medical Devices Agency) and SGK (Social Security Institution) processes.
Source
Pharmacy Times: FDA Approves Milestone Oral Therapy for Adults With Thalassemia, Anemia
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Thalassemia
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.